

Edgar Filing: Ultragenyx Pharmaceutical Inc. - Form SC 13G/A

Ultragenyx Pharmaceutical Inc.
Form SC 13G/A
February 13, 2015

SCHEDULE 13G

Amendment No. 1

ULTRAGENYX PHARMA INC

COMMON STOCK

Cusip #90400D108

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

Cusip #90400D108

Item 1: Reporting Person - FIL Limited

Item 2: (a)

(b)

Item 4: Bermuda

Item 5: 517,014

Item 6: 0

Item 7: 517,014

Item 8: 0

Item 9: 517,014

Item 11: 1.620%

Item 12: FI

Cusip #90400D108

Item 1: Reporting Person - Pandanus Partners, L.P.

Item 2: (a)

(b)

Item 4: Delaware

Item 5: 0

Item 6: 0

Item 7: 517,014

Item 8: 0

Item 9: 517,014

Item 11: 1.620%

Item 12: PN

Cusip #90400D108

Item 1: Reporting Person - Pandanus Associates, Inc.

Item 2: (a)

(b)

Item 4: Delaware

Item 5: 0

Item 6: 0

Item 7: 517,014

Item 8: 0

Item 9: 517,014

Item 11: 1.620%

Item 12: CO

Item 1(a). Name of Issuer:

ULTRAGENYX PHARMA INC

Item 1(b). Address of Issuer's Principal Executive Offices:

60 LEVERONI COURT
Novato, CA 94949
USA

Item 2(a). Name of Person Filing:

Edgar Filing: Ultragenyx Pharmaceutical Inc. - Form SC 13G/A

FIL Limited

Item 2(b).
Residence:

Address or Principal Business Office or, if None,

HM19

Pembroke Hall, 42 Crow Lane, Hamilton, Bermuda,

Item 2(c).

Citizenship:

Not applicable

Item 2(d).

Title of Class of Securities:

COMMON STOCK

Item 2(e).

CUSIP Number:

90400D108

Item 3.

Not Applicable

Item 4.

Ownership

(a) Amount Beneficially Owned: 517,014

(b) Percent of Class: 1.620%

(c) Number of shares as to which such person has:

517,014

(i) sole power to vote or to direct the vote:

(ii) shared power to vote or to direct the vote: 0

disposition of:

(iii) sole power to dispose or to direct the
517,014

disposition of:

(iv) shared power to dispose or to direct the
0

Item 5.

Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof, the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following (X).

Item 6.
Person.

Ownership of More than Five Percent on Behalf of Another

Not applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

See attached Exhibit A.

Item 8.

Identification and Classification of Members of the Group.

Edgar Filing: Ultragenyx Pharmaceutical Inc. - Form SC 13G/A

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certifications.

In as much as the reporting persons are no longer the beneficial owners of more than five percent of the number of shares outstanding, the reporting persons have no further reporting obligation under Section 13(d) of the Securities and Exchange Commission thereunder, and the reporting persons have no obligation to amend this Statement if any material change occurs in the facts set forth herein.

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 13, 2015
Date

/s/ Scott C. Goebel
Signature

Scott C. Goebel

Duly authorized under Power of Attorney effective as of May 5, 2014, by and on behalf of FIL Limited and its direct and indirect subsidiaries*

* This power of attorney is incorporated herein by reference to Exhibit B to the Schedule 13G filed by FIL Limited on June 10, 2014, accession number: 0000318989-14-000096.

Exhibit A

Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G.

| Entity | ITEM 3 Classification |
|-------------------------------|-----------------------|
| FIL INVESTMENTS INTERNATIONAL | FI |

Pandanus Partners, L.P. ("Pandanus") owns shares of FIL Limited ("FIL") voting stock. While the percentage of total voting power represented by these shares of FIL voting stock may fluctuate as a result

Edgar Filing: Ultragenyx Pharmaceutical Inc. - Form SC 13G/A

of changes in the total number of shares of FIL voting stock outstanding from time to time, it normally represents more than 25% and less than 50% of the total votes which may be cast by all holders of FIL voting stock. Pandanus Associates, Inc. ("PAI") acts as general partner of Pandanus. Pandanus is owned by trusts for the benefit of members of the family of Edward C. Johnson 3d but disclaims that any such member is a beneficial owner of the securities reported on this Schedule 13G.

This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FIL, certain of its subsidiaries and affiliates, and other companies (collectively, the "FIL Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FIL Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998).

RULE 13d-1(k)(1) AGREEMENT

The undersigned persons, on February 13, 2015, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of ULTRAGENYX PHARMA INC at December 31, 2014.

FIL Limited

By /s/ Scott C. Goebel
Scott C. Goebel

Duly authorized under Power of Attorney effective as of May 5, 2014, by and on behalf of FIL Limited and its direct and indirect subsidiaries*

Pandanus Partners, L.P.

By /s/ Scott C. Goebel
Scott C. Goebel

Duly authorized under Power of Attorney effective as of May 2, 2014, by Pandanus Associates, Inc. on behalf of Pandanus Partners, L.P.*

Pandanus Associates, Inc.

By /s/ Scott C. Goebel
Scott C. Goebel

Duly authorized under Power of Attorney effective as of May 2, 2014, by and on behalf of Pandanus Associates, Inc.*

* This power of attorney is incorporated herein by reference to Exhibit B to the Schedule 13G filed by FIL Limited on June 10, 2014, accession number: 0000318989-14-000096.